LLY : Summary for Eli Lilly and Company Common St - Yahoo Finance

U.S. Markets closed

Eli Lilly and Company (LLY)


NYSE - NYSE Real Time Price. Currency in USD
Add to watchlist
67.38-0.42 (-0.62%)
At close: 4:01 PM EST

67.14 -0.24 (-0.36%)
After hours: 7:49 PM EST

People also watch:
BMYMRKABTGSKJNJ
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close67.80
Open67.25
Bid67.05 x 900
Ask67.39 x 200
Day's Range66.56 - 67.38
52 Week Range64.18 - 87.21
Volume5,716,603
Avg. Volume5,343,668
Market Cap71.1B
Beta0.13
PE Ratio (TTM)29.31
EPS (TTM)N/A
Earnings DateN/A
Dividend & Yield2.04 (3.01%)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Better Buy: Johnson & Johnson vs. Eli Lilly
    Motley Fool6 hours ago

    Better Buy: Johnson & Johnson vs. Eli Lilly

    Eli Lilly's Alzheimer’s program is a bust. Does the market’s overreaction make this Big Pharma stock more attractive than Johnson & Johnson's right now?

  • American City Business Journals13 hours ago

    Can Biogen solve the Alzheimer’s drug riddle? We could find out within days

    Thursday is shaping up to be one of the most important days for Biogen in recent memory, as the Cambridge biotech prepares to announce data from a trial of a potentially groundbreaking — and extremely lucrative — Alzheimer’s drug. Biogen (BIIB) has a lot riding on the early-stage results for aducanumab, which are scheduled to be announced at the Clinical Trials for Alzheimer's Disease, an annual industry conference in San Diego. The recent failure of a similar Alzheimer’s treatment at Eli Lilly (LLY) cast doubt on the theory that amyloid causes memory loss, and sent Biogen’s share price tumbling .

  • Lilly: Jardiance Label to Add Cardiovascular Indication
    Zacksyesterday

    Lilly: Jardiance Label to Add Cardiovascular Indication

    Eli Lilly & Company (LLY) recently announced that the FDA has approved the inclusion of cardiovascular (CV) risk reduction data from the EMPA-REG OUTCOME study on its type II diabetes drug Jardiance's (SGLT-2 inhibitor) label.